Holocene Advisors, LP Fate Therapeutics Inc Transaction History

Holocene Advisors, LP

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$3.54 - $8.35 $8.95 Million - $21.1 Million	2,527,747 New	2,527,747 $18.6 Million
Q4 2021 Feb 14, 2022	SELL	$47.84 - $64.34 $11.4 Million - $15.3 Million	-238,576 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$59.27 - $95.73 $95,721 - $154,603	-1,615 Reduced 0.67%	238,576 $14.1 Million
Q2 2021 Aug 16, 2021	BUY	$67.25 - $92.52 $16.2 Million - $22.2 Million	240,191 New	240,191 $20.8 Million

178

113M

53.7K

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $129M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

Get notified when there are updates to the investment portfolio of Holocene Advisors, LP, based on Form 13F filings with the SEC.

Stay updated on Holocene Advisors, LP with notifications on news.